Edition:
United Kingdom

Pulmatrix Inc (PULM.OQ)

PULM.OQ on NASDAQ Stock Exchange Global Market

0.49USD
20 Jul 2018
Change (% chg)

$0.00 (+0.99%)
Prev Close
$0.48
Open
$0.48
Day's High
$0.50
Day's Low
$0.48
Volume
19,679
Avg. Vol
247,526
52-wk High
$2.67
52-wk Low
$0.41

Latest Key Developments (Source: Significant Developments)

Pulmatrix Announces Positive Top-Line Preliminary Results From Part 3 Of The 3-Part Phase 1/1B Clinical Trial Of Pulmazole
Tuesday, 17 Jul 2018 

July 17 (Reuters) - Pulmatrix Inc ::PULMATRIX ANNOUNCES POSITIVE TOP-LINE PRELIMINARY RESULTS FROM PART 3 OF THE 3-PART PHASE 1/1B CLINICAL TRIAL OF PULMAZOLE - AN INHALED DRY-POWDER ISPERSE™ FORMULATION OF ITRACONAZOLE.ALL OBJECTIVES FROM PART 3 SUCCESSFULLY MET.WITH PHASE 1/1B RESULTS FROM PART 3 NOW ALSO IN HAND, PULMATRIX PLANS TO INITIATE A PHASE 2 TRIAL IN ABPA PATIENTS IN Q4 2018.PULMAZOLE WAS SAFE AND WELL TOLERATED ADMINISTERED AS A SINGLE-DOSE OF 20 MG INHALED ITRACONAZOLE IN ASTHMATIC SUBJECTS.  Full Article

Pulmatrix posts Q3 net loss of $0.22 per share
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Pulmatrix Inc :Pulmatrix provides Q3 2017 highlights and Q3 2017 updated financials.Q3 revenue $300,000 versus $100,000.Qtrly ‍net loss per share attributable to common stockholders $0.22​.As of September 30, 2017, Pulmatrix had $6.4 million in cash and cash equivalents, compared to $4.2 million as of December 31, 2016​.  Full Article

FDA grants orphan drug status to Pulmatrix's PUR1900
Wednesday, 17 Aug 2016 

Pulmatrix Inc : Pulmatrix receives orphan drug designation from the FDA for inhaled drug to treat pulmonary fungal infections in cystic fibrosis patients .FDA granted co's request for orphan drug status for drug for treating pulmonary fungal infections in cystic fibrosis patients, named PUR1900.  Full Article

Pulmatrix reports quarterly loss per share $0.62
Thursday, 4 Aug 2016 

Pulmatrix Inc : Quarterly loss per share $0.62 .Revenues for Q2 of 2016 were $0.3 million, compared to $0.2 million for Q2 of 2015.  Full Article

BRIEF-Pulmatrix Announces Pricing Of $15.2 Million Underwritten Public Offering

* PULMATRIX ANNOUNCES PRICING OF $15.2 MILLION UNDERWRITTEN PUBLIC OFFERING